Key result
Single-dose cyclosporine at reperfusion reduces 6-month infarct size ~24% in acute MI.
Why the study?
Does a single dose of cyclosporine administered at the time of reperfusion improve left ventricular remodeling and reduce infarct size in patients with acute myocardial infarction?
RCT (n=28)
Does a single dose of cyclosporine administered at the time of reperfusion improve left ventricular remodeling and reduce infarct size in patients with acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
A single dose of cyclosporine at the time of reperfusion for acute myocardial infarction persistently reduces infarct size and attenuates LV dilation at 6 months.
OBJECTIVES This study examined the effect of a single dose of cyclosporine administered at the time of reperfusion on left ventricular (LV) remodeling and function by cardiac magnetic resonance 5 days and 6 months after myocardial infarction. BACKGROUND In a human study, administration of cyclosporine at the time of acute reperfusion was associated with a smaller infarct size. METHODS Twenty-eight patients of the original cyclosporine study had an acute (at 5 days) and a follow-up (at 6 months) cardiac magnetic resonance study to determine LV volumes, mass, ejection fraction, myocardial wall thickness in infarcted and remote noninfarcted myocardium, and infarct size. RESULTS There was a persistent reduction in infarct size at 6 months in the cyclosporine group compared with the control group of patients (29 +/- 15 g vs. 38 +/- 14 g; p = 0.04). There was a significant reduction of LV end-systolic volume (and a trend for LV end-diastolic volume; p = 0.07) in the cyclosporine group compared with the control group, both at 5 days and 6 months after infarction. There was no significant difference between the 2 groups in either global LV mass or regional wall thickness of the remote noninfarcted myocardium at 5 days or 6 months. Attenuation of LV dilation and improvement of LV ejection fraction by cyclosporine at 6 months were correlated with infarct size reduction. CONCLUSIONS Cyclosporine used at the moment of acute myocardial infarction reperfusion persistently reduces infarct size and does not have a detrimental effect on LV remodeling. These results are preliminary and must be supported by further studies. (Ciclosporin A and Acute Myocardial Infarction; NCT00403728).
No takes yet. Share an insight, caveat, or question.
Mewton et al. (2010) conducted an RCT in Reperfused Myocardial Infarction (n=28). Cyclosporine vs. control group was evaluated on Infarct size at 6 months (p=0.04). A single dose of cyclosporine administered at the time of acute myocardial infarction reperfusion persistently reduced infarct size at 6 months (29 ± 15 g vs. 38 ± 14 g; p=0.04).
Synapse has enriched 5 related papers. Consider them for comparative context: